Teleflex has completed the previously announced acquisition of US-based medical equipment manufacturer NeoTract for approximately $1.1bn.

As part of the deal, Teleflex bought NeoTract for an upfront cash payment of $725m at closing, and up to an additional $375m after the achievement of select commercial milestones associated with sales until the end of 2020.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Teleflex will have access to NeoTract’s FDA-cleared UroLift System, a minimally invasive technology developed to treat lower urinary tract symptoms caused by benign prostatic hyperplasia (BPH).

Through a transurethral outpatient procedure, UroLift delivers permanent implants to hold open the urethra and to minimise prostate obstruction without cutting, heating or removing the prostate tissue.

Teleflex offers solutions in the fields of vascular and interventional access, surgical, anaesthesia, cardiac care, urology, emergency medicine, and respiratory care.

“The addition of NeoTract is expected to improve Teleflex’s presence in the urological market.”

The Teleflex family consists of Arrow, Deknatel, Hudson RCI, LMA, Pilling, Rusch, and Weck brands.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The addition of NeoTract is expected to improve Teleflex’s presence in the urological market as UroLift is used to address a significant medical issue and targets a total addressable $39bn market.

Since receipt of CE-Mark in 2010 and de novo 510(k) in 2013, UroLift has been the subject of a significant number of studies, including two randomised clinical trials, seven open-label studies, and three meta-analyses.

The system also has broad, sustainable reimbursement in place, including dedicated category 1 CPT codes specific to the UroLift System procedure and is 100% covered by Medicare Administrative Contractors, which translates to approximately 174 million lives in the US.